Skip to search formSkip to main contentSkip to account menu

CH 5137291

Known as: CH-5137291, CH5137291 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance… 
2013
2013
Dispersity and bioavailability of highly drug-loaded PEG 400 formulation is improved with micellar technology
SUMMARY A micellar formulation improved the dispersity of PEG400 with a high load of CH5137291 (Drug-A), and enhanced… 
2012
2012
High drug loading self-microemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation
Purpose: To design a high drug loading formulation of self-microemulsifying/micelle system. Methods: A poorly-soluble model drug… 
2011
2011
Biological properties of androgen receptor pure antagonist for treatment of castration‐resistant prostate cancer: Optimization from lead compound to CH5137291
Castration‐resistant prostate cancer (CRPC) is still dependent on androgen receptor (AR) signaling. We previously reported that a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)